NOTE: The content below contains the first few paragraphs of the printed article and the titles of the sidebars and boxes, if applicable.
DR. JOHN ORLOFF
Baxter Appoints VP of BioScience R&D
Baxter International has appointed John Orloff, M.D., as VP and global head of research and development for Baxter BioScience.
Dr. Orloff joins Baxter from Merck Serono Pharmaceuticals, where he served as global head of clinical development. Dr. Orloff is responsible for advancing the late-stage bioscience pipeline, enhancing the current R&D operating model, and pursuing additional innovative opportunities for the business.
DR. LUCIANO ROSSETTI
Merck KGaA Names R&D Head
Merck KGaA’s biopharmaceutical division has appointed Luciano Rossetti, M.D., as executive VP and global head of research and development.
Before joining Merck KGaA, Dr. Rossetti was senior VP late stage development at Merck & Co., where he was responsible for the development from Phase II to Phase V across all therapeutic areas.
Voyager Therapeutics Appoints
Senior VP of Regulatory Affairs
Voyager Therapeutics, a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (CNS), has named industry veteran Robert Pietrusko, Pharm.D., as senior VP of regulatory affairs.
Dr. Pietrusko brings to Voyager more than three decades of experience in regulatory affairs and pharmaceutical drug development across a range of categories, including CNS disorders, and has been instrumental in the worldwide approval of more than 30 medicines or new indications.
Before Voyager, Dr. Pietrusko was VP, global regulatory affairs and quality and executive officer at ViroPharma.
Dr. STEPHAN KUTZER
AAIPharma Services and
Cambridge Major Laboratories
AAIPharma Services Corp., a global provider of pharmaceutical analytical testing, product development, and manufacturing services, and Cambridge Major Laboratories, a global leader in pharmaceutical API development and manufacturing, have appointed Stephan Kutzer, Ph.D. as CEO.
Most recently, Dr. Kutzer served as chief operating officer of Lonza, part of the Lonza Group, a Swiss chemicals and biotechnology company.
DR. ROGER POMERANTZ
Flagship Ventures Adds Pharma
Flagship Ventures, a venture capital and venture creation firm focused on healthcare and sustainability, has appointed Roger J. Pomerantz, M.D., as a senior partner. In this role, Dr. Pomerantz provides strategic counsel and support to the Flagship team as well as to portfolio companies through board and advisory roles.
Dr. Pomerantz recently joined as president and CEO of Seres Health, a Flagship VentureLabs-founded company. Seres Health is a clinical-stage therapeutics company developing novel treatments for diseases related to the human microbiome.
Zitter Health Insights
Zitter Health Insights, a healthcare research firm focusing on product access, reimbursement, and managed markets, has hired John Monahan as president.
Most recently Mr. Monahan was senior VP of corporate services for Barnabas Health, New Jersey’s largest integrated healthcare system.
A seasoned healthcare and business services executive, he brings more than 20 years of leadership experience to Zitter Health Insights.
Deloitte Names Practice Lead
Deloitte has named Homi Kapadia as the organization’s vice chairman and leader of its national life-sciences industry practice. His responsibilities include guiding the life-sciences practice and deliver a cross-sector viewpoint to clients.
With more than 28 years of experience at Deloitte, including advising market-leading organizations and holding oversight roles within the life sciences practice, Mr. Kapadia is based in Philadelphia and succeeds Terry Hisey in his new role.
Giant Creative/Strategy Opens
Philadelphia Offices With
Giant Creative/Strategy, a full-service independent healthcare communications agency on the West Coast, recently expanded its presence to the East Coast by opening a full-service office in Philadelphia.
A group of senior-level professionals is leading the fully integrated strategy and campaign development at the Philadelphia location. The team includes: Becky Bodenner, senior VP, group creative director, who formerly worked at Dudnyk; Rebecca Greenberg, senior VP, managing director, who was previously at Juice Pharma Worldwide; Tom Jakab, Senior VP, group creative director, who joined Giant from CDM Princeton; and Eric Steckelman, Senior VP, managing director, is the lead liaison to San Francisco.
DR. REZA HAQUE
Shire Ophthalmics Business
Unit Names Head
Shire’s recently formed ophthalmics business unit (BU) has appointed Reza Haque, M.D., Ph.D., as therapeutic area head. Dr. Haque is responsible for overseeing the continued development of lifitegrast, the company’s retinopathy of prematurity (ROP) product, and any future molecules in ophthalmics.
Most recently, he served as global program head and head of professional afairs North America at Bausch + Lomb, Inc., where he led cross-functional teams though all aspects of the clinical development program.
Dr. Yan Moore
Dr. Piet A.M Vervaet
Ariad Names Three Key Appointments
Ariad has made three appointments in the areas of global quality, medical affairs, and drug safety and pharmacovigilance: Timothy Maines, VP, quality; Yan Moore, M.D., VP, medical affairs; Piet A.M Vervaet, M.D., VP, drug safety and pharmacovigilance.
Mr. Maines leads the global quality function and has put in place systems to ensure quality and compliance in clinical, manufacturing and laboratory good practices. Before joining Ariad, Mr. Maines served as VP, quality, at Omthera Pharmaceuticals, where he was responsible for quality and technical GXP operations.
Dr. Moore leads global medical affairs and is responsible for investigator-sponsored clinical-research activities, publications, medical information, key therapeutic leader engagement, medical affairs planning for the company’s pipeline of oncology products and in collaboration with others, for life-cycle management of Iclusig (ponatinib) and strategic planning for its current and future clinical indications. Before joining Ariad, Dr. Moore served as associate VP, global medical affairs at Sanofi, where he was responsible for global medical affairs, clinical development and business opportunities for the company’s gastrointestinal and other solid-tumor products.
Dr. Vervaet leads global safety and pharmacovigilance and is responsible for safety surveillance, risk identification and risk management for Ariad’s marketed and pipeline of oncology products, as well as proper risk communications to patients, healthcare professionals and health authorities. Before joining Ariad, Dr. Vervaet served as VP, drug safety and pharmacovigilance, at Onyx Pharmaceuticals, where he was responsible for the strategic leadership and oversight for the pharmacovigilance and drug-safety function and focused on proactive and timely risk-benefit assessments of clinical data to characterize the safety profiles of the company’s oncology portfolio.
Dr. Bert Bakker
Versartis Appoints Endocrinologist to Lead Medical Affairs
Versartis, an endocrine-focused biopharmaceutical company that is developing VRS-317, a novel, long-acting form of recombinant human growth hormone (rhGH) for the treatment of growth hormone deficiency (GHD), has added Bert Bakker, M.D., Ph.D., to its executive team as senior VP, medical affairs.
Most recently, Dr. Bakker was global brand medical director, global medical affairs, at Novartis Oncology where he led and developed the global medical affairs strategy for the use of two somatostatin analogs in neuro-endocrine tumors and oversaw a number of early clinical development studies.
Dr. Ian Friedland
Chief Medical Officer
Achaogen, a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant (MDR) gram-negative infections, has named Ian Friedland, M.D., as chief medical officer. In this position, his responsibilities include leadership of the pivotal Phase III trial for plazomicin, Achaogen’s lead product for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE).
Before joining Achaogen, Dr. Friedland served as VP, clinical development at Cubist Pharmaceuticals.
JULIE ANN SMITH
Raptor Announces CEO
Raptor Pharmaceuticals has appointed Julie Anne Smith, executive VP, president, strategy and chief operating officer at Raptor, and she has been named president and CEO-designate effective immediately. Ms. Smith will succeed Christopher Starr, Ph.D., as CEO, Jan. 1, 2015.
Ms. Smith joined Raptor in September 2012 as executive VP, strategy and chief operating officer, where she led the development of the commercial strategy and infrastructure to support the approval and launch of Procysbi, Raptor’s first commercial product.
Forum Pharmaceuticals Names VP,
Forum Pharmaceuticals (previously known as EnVivo Pharmaceuticals), a biotechnology company singularly focused on the development and delivery of innovative medicines to treat serious brain diseases, has appointed Christine Boisclair VP, regulatory affairs. In this role, she will provide oversight for all aspects of the company’s U.S. and international regulatory matters. Ms. Boisclair brings more than 20 years of regulatory affairs experience in the biotechnology and pharmaceutical industries to her role.
Ms. Boisclair most recently served as VP, regulatory affairs, at Insmed.
InVivo Therapeutics Announces New
Responsibilities for Senior Manage
ment Team Members
Lisa Crockett has been appointed VP, regulatory affairs and reimbursement planning, at InVivo Therapeutics Holdings Corp. Previously, she held the position of VP, regulatory affairs. She joined InVivo in June of 2013 from Genzyme, where she most recently served as associate director of regulatory affairs.
William D’Agostino, has been appointed senior VP, Operations. Previously, he held the position of VP, manufacturing and engineering. He joined InVivo in September 2012. Previously, he held the position of VP, engineering, at Angiotech Pharmaceuticals.
Kristin Neff has been appointed VP, clinical operations and project management. Previously, she held the position of VP, clinical operations. Ms. Neff joined InVivo in August 2013 from Taris Biomedical where she served as senior director, clinical operations.
Dr. TONY FIORINO
BrainStorm Cell Names CEO
BrainStorm Cell Therapeutics, a developer of adult stem cell technologies for neurodegenerative diseases, has appointed Tony Fiorino, M.D., Ph.D., as CEO
Dr. Fiorino brings to BrainStorm broad and extensive experience in both biotechnology finance and drug development. Before joining BrainStorm, he was a managing director at Greywall Asset Management, a healthcare equity fund.
Dr. James Gilbert
True North Therapeutics
Appoints Chief Medical Officer
True North Therapeutics, a biotechnology company developing novel therapies that selectively inhibit the complement system to treat rare diseases, has appointed James Gilbert, M.D., as chief medical officer (CMO). As CMO, Dr. Gilbert will oversee all clinical development and regulatory activities for the company, as True North advances its lead product candidate, TNT009, into human clinical trials for autoantibody-driven rare diseases that are mediated by the complement system.
Dr. Ronald Notvest
Tonix Appoints Senior VP
Tonix Pharmaceuticals Holding, a clinical-stage pharmaceutical company focused on common disorders of the central nervous system, has appointed Ronald Notvest, Ph.D., to its newly created position of senior VP, commercial planning and development.
Dr. Notvest joins Tonix from Evidec, where he applied his expertise in the commercial assessment and analysis of drug products on behalf of a variety of biopharmaceutical industry clients since founding the firm in 2002.
Acurian Strengthens Patient
Recruitment Efforts in Europe
Acurian, asubsidiary of PPD, has named Paul Mitchel as director of direct response marketing for Europe, the Middle East, and Africa.
In this role, Mr. Mitchel will continue to expand Acurian’s capabilities to recruit participants for clinical trials outside North America.